<P>Contact: Jacqueline Partarrieu<BR>press@escardio.org<BR>33-492-947-756<BR>European Society of Cardiology <BR>
<P>Lisbon, 27 May 2013: Ambulatory levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep Study presented today during the late breaking trial session1 of the Heart Failure Congress 2013. In a second study, the third generation mineralocorticoid receptor antagonist (MRA) BAY 94-8862 showed
No comments:
Post a Comment